NCT06465238View on ClinicalTrials.gov

Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
NSCLC
Interventions
DRUG

SHR-A2009

Treatment group: Subjects will receive an intravenous infusion of SHR-A2009 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.

DRUG

SHR-A1921

Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.

Trial Locations (1)

Unknown

Henan cancer hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV